An Enzyme-Linked Immunosorbent Assay (ELISA) for the Measurement of Plasmin-α₂-Antiplasmin Complex in Human Plasma - Application to the Detection of In Vivo Activation of the Fibrinolytic System

Summary

An enzyme-linked immunosorbent assay (ELISA) is developed for the measurement of plasmin-α₂-antiplasmin complex in human plasma. Microtiter plates were coated with a mixture of two murine monoclonal antibodies directed against human α₂-antiplasmin and bound plasmin-α₂-antiplasmin complex was quantitated with a peroxidase-conjugated monoclonal antibody directed against human plasminogen. The lower limit of sensitivity of the assay was 0.01 nM of plasmin-α₂-antiplasmin complex in 100-fold diluted human plasma, allowing detection of 1 nM in undiluted plasma samples. After 100-fold dilution of the plasma samples, the assay was no longer influenced by the presence of the precursors plasminogen and α₂-antiplasmin.

At a concentration of 2.0 nM of plasmin-α₂-antiplasmin complex in plasma, intra- and interassay variation coefficients were 4.2 and 5.5 percent respectively. In plasma samples of 25 control subjects the levels of plasmin-α₂-antiplasmin complex were below 1 nM. Extensive in vivo activation of the fibrinolytic system during thrombolytic therapy with streptokinase resulted in the generation of elevated levels of plasmin-α₂-antiplasrnin complex up to 690 ± 150 nM.

No measurable levels of plasmin-α₂-antiplasmin complex were found in the plasma of 32 patients with acute deep vein thrombosis nor in the plasma of 11 patients with recurrent deep vein thrombosis.

These findings indicate that plasmin-α₂-antiplasmin complex is generated during in vivo activation of the fibrinolytic system and that its assay may be useful to monitor thrombolytic therapy but not for the diagnosis of venous thrombosis.

Key words

ELISA - Plasmin-α₂-antiplasmin complex - Monoclonal antibodies

• References

• 1 Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979; 53: 313-324
• 2 Collen D, Cock FDe. Emergence in plasma during activation of the coagulation or fibrinolytic system of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors. Thromb Res 1974; 5: 777-779
• 3 Plow EF, Cock FDe, Collen D. Immunochemical characterization of the plasmin-antiplasmin system: basis for the specific detection of the plasmin-antiplasmin complex by latex agglutination assays. J Lab Clin Med 1973; 93: 199-209
• 4 Wiman B, Jacobsson L, Andersson M, Mellbring G. Determination of plasmin-α₂-antiplasmin complex in plasma samples by means of a radioimmunoassay. Scand J Clin Lab Invest 1983; 43: 27-33
• 5 Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemostas 1980; 43: 77-89
• 6 Harpel PC. α₂-Antiplasmin inhibitor and α₂-macroglobulin-plasmin complexes in plasma. J Clin Invest 1981; 68: 46-55
• 7 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem 1985; 260: 12106-12111
• 8 Wiman B, Collen D. On the mechanism of the reaction between human α₂-antiplasmin and plasmin. J Biol Chem 1979; 254: 9291-9297
• 9 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
• 11 Harpel PC. Human α₂-macroglobulin. Meth Enzymol 1976; 45: 639-652
• 12 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 13 Gaffney PJ, Curtis AD. A collaborative study of a proposed International Standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
• 14 Kearney JF, Radbruch A, Liesegang B, Rajewski K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of anti-body-secreting hybrid cell lines. J Immunol 1979; 123: 1548-1550
• 15 Galfré G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Meth Enzymol 1981; 73: 3-46
• 16 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG₁, IgG_2a and IgG_2b immunoglobulins from mouse serum using protein A-Sephar-ose. Immunochemistry 1978; 15: 429-436
• 17 Stähli C, Miggiano V, Stocker J, Staehelin T, Häring P, Takacs B. Distinction of epitopes by monoclonal antibodies. Meth Enzymol 1983; 92: 242-253
• 18 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
• 19 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody directed against the high affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis. Eur J Biochem 1986; 157: 65-69
• 20 Paramo JA, de Boer A, Colucci M, Jonker J JC, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep-vein thrombosis. Thromb Haemostas 1985; 54: 725
• 21 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 1985; 54: 684-687
• 22 Nakane PA, Kawaoi A. Peroxidase labeled antibody. A new method of conjugation. J Histochem Cytochem 1974; 22: 1084-1091
• 23 Bergsdorf N, Nilsson T, Wallén P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744